Immuneering presents preclinical data on IMM-1-104 at AACR 2024

Immuneering Corporation presented preclinical data at the American Association for Cancer Research Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors. In a poster titled, “Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models,” IMM-1-104, gemcitabine, nab-paclitaxel, and 5-fluorouracil were evaluated in tumor xenograft models alone or across multiple combinations. Results: IMM-1-104 showed promising combination effects when treated with gemcitabine, paclitaxel or fluorouracil in 3D-tumor growth assay pancreatic cancer models. IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer. In a human pancreatic cancer cell line (MIA PaCa-2) tumor xenograft model, IMM-1-104 alone showed greater tumor growth inhibition and better durability than any single or combination chemotherapy tested. At day 39, antitumor activity was 103% for IMM-1-104 at 125 mg/kg BID PO, 25.2% for GEM at 60 mg/kg IP Q4D, 62.2% for PAC at 10 mg/kg IV Q4D, and 36.6% for 5FU at 50 mg/kg IP Q4D. In the Phase 2a portion of Immuneering’s ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in select combinations with approved chemotherapeutic agents. The Phase 2a portion includes five arms, three of which focus on patients with pancreatic cancer. Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting. The company expects initial data from multiple Phase 2a arms in 2024.